Skip to main content

Table 2 Progression-free survival results for patient characteristics and biomarkers

From: The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study

 

N

No.

Events

Median

Years

HR

95 % CI

for HR

HR

p-value

Race

 Non-White

9

9

1.77

   

 White

57

57

1.93

1.20

(0.57, 2.54)

0.64

Gleason score

 5–7

13

13

3.59

   

 8–10

51

51

1.60

1.77

(0.94, 3.34)

0.08

Performance Status

 0

31

31

1.97

   

 1–2

35

35

1.70

1.20

(0.74, 1.96)

0.46

Metastatic Volume

 Low

31

31

3.53

   

 High

35

35

1.27

2.93

(1.70, 5.05)

<0.001

Treatment

 ADT

34

34

1.60

   

 ADT + Chemo

31

31

2.29

0.99

(0.60, 1.61)

0.95

Diabetes

 No

62

62

1.93

   

 Yes

4

4

0.92

2.28

(0.80, 6.45)

0.12

Age

66

66

1.77

0.99

(0.96, 1.02)

0.67

PSA (ln)

66

66

1.77

1.00

(0.99, 1.01)

0.65

Insulin (ln)

66

66

1.77

0.81

(0.67, 0.98)

0.03

RANK (ln)

66

66

1.77

0.82

(0.60, 1.12)

0.22

IGFBP3 (ln)

66

66

1.77

0.89

(0.52, 1.51)

0.66

IGFBP1 (ln)

66

66

1.77

1.05

(0.87, 1.27)

0.59

IGF I

66

66

1.77

0.85

(0.42, 1.74)

0.66

IGF II

66

66

1.77

0.80

(0.27, 2.42)

0.70

HGF (ln)

66

66

1.77

1.63

(1.06, 2.51)

0.03

OPN

66

66

1.77

1.56

(1.13, 2.15)

0.01

C-peptide (ln)

66

66

1.77

0.62

(0.39, 1.00)

0.05

PD1 (ln)

66

66

1.77

0.82

(0.53, 1.25)

0.35

IL6 (ln)

66

66

1.77

1.26

(0.91, 1.75)

0.17

OPG (ln)

66

66

1.77

0.97

(0.84, 1.11)

0.63

  1. PSA prostate specific antigen, RANK Receptor Activator of Nuclear Factor k B, IGFBP insulin-like growth factor binding protein, IGF insulin-like growth factor, HGF hepatocyte growth factor, OPN osteopontin, PD1 Programmed cell death protein 1, IL6 interleukin-6, OPG Osteoprotegerin
  2. For continuous measures, the HR is based on a one unit difference in the measurement